Home › Research › Costs and economics
Costs of Care in Relation to Alzheimer's Disease Severity in Sweden: A National Registry-Based Cohort Study
Aye S, Frisell O, Zetterberg H, Skillbäck TB, Kern S, Eriksdotter M, Aho E, Xia X, Winblad B, Wimo A, Jönsson L. PharmacoEconomics, 2024-11-01
Topic: Amyloid, tau and blood-test diagnosis
Results Mean annual costs for individuals with clinically diagnosed AD were SEK 99,906, SEK 290,972, SEK 479,524, and SEK 795,617 in mild cognitive impairment (MCI), mild, moderate, and severe AD.
Key findings
- Results Mean annual costs for individuals with clinically diagnosed AD were SEK 99,906, SEK 290,972, SEK 479,524, and SEK 795,617 in mild cognitive impairment (MCI), mild, moderate, and severe AD.
Why it matters
This registry-based cohort study found mean annual costs for individuals with clinically diagnosed Alzheimer's disease of SEK 99,906 in mild cognitive impairment, SEK 290,972 in mild, SEK 479,524 in moderate, and SEK 795,617 in severe disease. It describes costs by severity and does not test any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designcohort
- Participants95,853
- Effect sizeAnnual costs SEK 99,906 (MCI) to SEK 795,617 (severe AD); SEK 57,625 to 668,073 in amyloid-confirmed patients
- Evidence strengthHigh
Limitations
Informal care costs were not included because the registries do not collect them, and the retrospective registry design relies on routinely collected data; MCI was identified retrospectively as visits within five years before an AD diagnosis.
How this study scored 63/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomised / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 62 of the 98 points we could judge it on, which is 63 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (PharmacoEconomics) |
| Journal's citation record | 2 / 4 | PharmacoEconomics: journal h-index 153 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 95,853 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Linus Jönsson: h-index 55 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39485581) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 62 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 62 of the 98 points we could judge it on is 63 out of 100. |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 11 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Aye, S., Frisell, O., Zetterberg, H., Skillbäck, T. B., Kern, S., Eriksdotter, M., et al. (2025). Costs of Care in Relation to Alzheimer's Disease Severity in Sweden: A National Registry-Based Cohort Study. PharmacoEconomics. https://doi.org/10.1007/s40273-024-01443-2
Vancouver
Aye S, Frisell O, Zetterberg H, Skillbäck TB, Kern S, Eriksdotter M, et al. Costs of Care in Relation to Alzheimer's Disease Severity in Sweden: A National Registry-Based Cohort Study. PharmacoEconomics. 2025. doi:10.1007/s40273-024-01443-2. PMID: 39485581.
BibTeX
@article{aye2025-39485581,
author = {Aye, S. and Frisell, O. and Zetterberg, H. and Skillbäck, T. B. and Kern, S. and Eriksdotter, M. and Aho, E. and Xia, X. and Winblad, B. and Wimo, A. and Jönsson, L.},
title = {{Costs of Care in Relation to Alzheimer's Disease Severity in Sweden: A National Registry-Based Cohort Study}},
journal = {PharmacoEconomics},
year = {2025},
doi = {10.1007/s40273-024-01443-2},
pmid = {39485581},
url = {https://doi.org/10.1007/s40273-024-01443-2}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Costs and economics
Also in Costs and economics
21 studies in the library are filed under Costs and economics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Costs and economics hub.